Global Information
회사소개 | 문의

세계의 방출제어 약물전달 시장 : 시장 기회, 임상 파이프라인 분석과 예측(-2025년)

Global Controlled Release Drug Delivery Market Opportunity & Clinical Trial Outlook 2025

리서치사 KuicK Research
발행일 2018년 11월 상품 코드 749539
페이지 정보 영문 700 Pages
가격
US $ 2,400 ₩ 2,734,500 PDF by E-mail (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1명만 이용할 수 있으며 편집 및 인쇄가 불가능합니다.
US $ 3,300 ₩ 3,760,000 CD-ROM
US $ 4,200 ₩ 4,785,400 Hard Copy
US $ 4,400 ₩ 5,013,300 PDF by E-mail (Multi-User License) help
동일 기업 내의 모든 직원들이 이용할 수 있는 라이선스입니다. 편집은 불가능하며 인쇄는 1회에 한해 가능합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 방출제어 약물전달 시장 : 시장 기회, 임상 파이프라인 분석과 예측(-2025년) Global Controlled Release Drug Delivery Market Opportunity & Clinical Trial Outlook 2025
발행일 : 2018년 11월 페이지 정보 : 영문 700 Pages

세계의 방출제어 약물전달(Controlled Release Drug Delivery) 시장을 조사했으며, 시장 정의와 개요, 시장 발전 역사, 방출제어의 메커니즘·기술·방식, 시장 성장 영향요인 및 시장 기회, 방출제어 약제의 임상 파이프라인과 출시된 약제 동향, 주요 사업자 개요, 향후 전망 등의 정보를 정리했습니다.

제1장 약물 전달 : 성장 궤도

제2장 방출제어 약물전달이란?

제3장 방출제어 약물전달 기술 개발

  • 1세대
  • 2세대

제4장 방출제어 약물전달의 기초 정보

  • 방출제어 약물전달의 전제조건
  • 방출제어 약물전달의 합리성

제5장 방출제어 메커니즘

  • 확산 제어
  • 용해 제어 시스템
  • 물 침투 제어 시스템
  • 침식 제어 시스템
  • 이온 교환 제어 시스템

제6장 방출제어 약물전달의 분류

  • 전달 시스템별
  • 기술별
  • 경로별

제7장 방출제어 약물전달의 각종 방식

  • 폴리머
  • Chronopharmaceutics
  • 나노입자 전달 시스템

제8장 방출제어약 임상 파이프라인 : 개요

  • 단계별
  • 국가 및 지역별
  • 작용기전별
  • 약제 클래스별
  • 적응증별

제9장 방출제어 약물전달의 각종 용도

  • 당뇨병
  • 심혈관 질환
  • 신경계 질환
  • 감염증

제10장 방출제어 약제의 설계

  • 경장 제제
    • 고형
    • 액체
    • 흡입제
  • 비경구제
    • 주사제
    • 이식 가능한 기기
  • 약제 방출의 일반 메커니즘

제11장 시장 동향

  • 투약 경로
  • 방식

제12장 시장 역학

  • 성장 촉진요인
  • 해결해야 할 과제

제13장 향후 전망

  • 진행중인 임상시험
  • 향후의 시장 기회

제14장 임상시험 : 기업, 적응증, 단계별

  • 불명
  • 연구 단계
  • 전임상 단계
  • 임상 단계
  • 제I상
  • 제I/II상
  • 제II상
  • 제II/III상
  • 제III상
  • 신청
  • 승인

제15장 출시된 약제

제16장 경쟁 환경

  • Allergan
  • Amylin Pharmaceuticals
  • AstraZeneca
  • BioAlliance Pharma
  • Biogen
  • Collegium Pharmaceutical
  • Controlled Therapeutics(Ferring Pharmaceuticals)
  • Cosmo Pharmaceuticals
  • Egalet
  • Elan Corporation
  • Encore Therapeutics
  • Flamel Technologies
  • GlaxoSmithKline
  • Heron Therapeutics
  • iCeutica
  • Mithra Pharmaceuticals
  • Neurim Pharmaceuticals
  • Novartis
  • Orexigen Therapeutics
  • Otsuka Pharmaceutical
  • Pfizer
  • Purdue Pharma
  • Syntex Pharmaceuticals International
  • Takeda
  • Zealand Pharma
LSH 18.12.06

"Global Controlled Release Drug Delivery Market Opportunity & Clinical Trial Outlook 2025" Report Highlights:

  • Development of Controlled Drug Delivery Technology
  • Approaches for Controlled Drug Delivery
  • Global Controlled Release Drug Clinical Pipeline by Phase, Indication, Drug Class
  • Global Controlled Release Drug Clinical Pipeline: 218 Drugs
  • Marketed Controlled Release Drugs: 118 Drugs
  • Majority Drugs In Phase-II & Phase-III Trials: More Than 80
  • Global Controlled Drug Delivery Market Future Outlook

Controlled drug delivery technology is the one of the most rapidly advancing area in human healthcare management and already had an enormous impact on medical technology with the potential to improve health. As the goal of any drug delivery system is to provide a therapeutic amount of drug to a proper site in the body so that the desired drug concentration can be achieved promptly and then maintained, all these characteristics are provided by controlled drug delivery technologies.

Controlled drug delivery systems provide uniform concentration of drug to the absorptions site and thus allow the maintenance of plasma concentration within the therapeutic range which minimizes not only the side effects but also the frequency of administration. The term controlled release has a meaning that goes beyond the scope of sustained drug action.

One of the major factors for the increased market tendencies for controlled drug delivery market is the improvement and advances in the use of varied approaches. Polymeric controlled drug delivery is the most applied strategy towards the controlled drug delivery. Polymers used for coating and in other forms consist of two forms synthetic and biodegradable polymers. The extensive usage of biodegradable polymers in medical devices is expected to push the global biodegradable polymers market.

The future of controlled drug delivery is quite fertile with respect to various upcoming systems and products which will be providing the controlled release mechanism. Some of the products have been launched and some will be coming soon as are under clinical investigations. Various depot systems are under construction, along with the approaches using nanoparticulate system, transdermal controlled deliveries and much more. Newer, more sophisticated, transdermal patches and other transdermal controlled drug delivery systems are being developed that are currently being tested in clinical trials.

KuicK Research report on the "Controlled Release Drug Delivery Market" is a result of intensive study of the novel segment and its future market potential. The report has been made with key focus on the current market trends, superiority of Controlled Drug Delivery methods to traditional drug delivery methods. The report also provides key insights into the technology and approaches of controlled delivered drugs, recent developments and market dynamics that might impact its future. The report concludes with comprehensive insight on ongoing clinical trials of controlled delivered drugs and future trends which clearly highlights it as one of the most promising market in the modern drug delivery segment.

Table of Contents

1. Drug Delivery: An Advancing Trajectory

  • 1.1. Preamble Towards Drug Delivery
  • 1.2. Ideal Mode of Drug Delivery System

2. What is Controlled Drug Delivery?

  • 2.1. Novel Drug Delivery Systems
  • 2.2. Preamble to Controlled Drug Delivery

3. Development of Controlled Drug Delivery Technology

  • 3.1. First Generation
  • 3.2. Second Generation

4. Basics of Controlled Drug Delivery

  • 4.1. Prerequisites of Controlled Delivery
  • 4.2. Rationale for Controlled Drug Delivery

5. Mechanism of Controlled Drug Release

  • 5.1. Diffusion Controlled
  • 5.2. Dissolution Controlled System
  • 5.3. Water Penetration Controlled System
  • 5.4. Erosion Controlled System
  • 5.5. Ion-Exchange Controlled System

6. Cataloging of Controlled Drug Delivery

  • 6.1. Classification Based Over Delivery Systems
  • 6.2. Classification Based Over Technicality
  • 6.3. Classification Based Over Routes

7. Approaches for Controlled Drug Delivery

  • 7.1. Polymers
  • 7.2. Chronopharmaceutics
  • 7.3. Nanoparticulate Delivery System

8. Global Controlled Release Drug Clinical Pipeline Overview

  • 8.1. Phase
  • 8.2. Country/Region
  • 8.3. Mode of Action
  • 8.4. Drug class
  • 8.5. Indication

9. Application of Controlled Drug Delivery

  • 9.1. Diabetes
  • 9.2. Cancer
  • 9.3. Cardiovascular Diseases
  • 9.4. Neurological Disorders
  • 9.5. Infections

10. Drug Designing for Controlled Delivery

  • 10.1. Enteral Dosage Formulations
    • 10.1.1. Solid Dosage Forms
    • 10.1.2. Liquid Dosage Forms
    • 10.1.3. Inhalation Dosage Forms
  • 10.2. Parenteral Dosage Forms
    • 10.2.1. Injectable Dosage Forms
    • 10.2.2. Implantable Device
  • 10.3. General Mechanisms of Drug Release

11. Market Inclinations

  • 11.1. Market over Routes of Administration
  • 11.2. Market over Approaches

12. Global Controlled Drug Delivery Market Dynamics

  • 12.1. Accelerative Parameters
  • 12.2. Challenges

13. Global Controlled Drug Delivery Market Future Outlook

  • 13.1. Ongoing Clinical Trials
  • 13.2. Future Market Opportunities

14. Global Controlled Drug Delivery Clinical Trials by Company, Indication and Phase

  • 14.1. Unknown
  • 14.2. Research
  • 14.3. Preclinical
  • 14.4. Clinical
  • 14.5. Phase-I
  • 14.6. Phase-I/II
  • 14.7. Phase-II
  • 14.8. Phase-II/III
  • 14.9. Phase-III
  • 14.10. Preregistration
  • 14.11. Registered

15. Marketed Controlled Release Drug Clinical Insight by Company, Indication and Phase

16. Competitive Landscape

  • 16.1. Allergan
  • 16.2. Amylin Pharmaceuticals
  • 16.3. AstraZeneca
  • 16.4. BioAlliance Pharma
  • 16.5. Biogen
  • 16.6. Collegium Pharmaceutical
  • 16.7. Controlled Therapeutics (Ferring Pharmaceuticals)
  • 16.8. Cosmo Pharmaceuticals
  • 16.9. Egalet
  • 16.10. Elan Corporation
  • 16.11. Encore Therapeutics
  • 16.12. Flamel Technologies
  • 16.13. GlaxoSmithKline
  • 16.14. Heron Therapeutics
  • 16.15. iCeutica
  • 16.16. Mithra Pharmaceuticals
  • 16.17. Neurim Pharmaceuticals
  • 16.18. Novartis
  • 16.19. Orexigen Therapeutics
  • 16.20. Otsuka Pharmaceutical
  • 16.21. Pfizer
  • 16.22. Purdue Pharma
  • 16.23. Syntex Pharmaceuticals International
  • 16.24. Takeda
  • 16.25. Zealand Pharma

List of Figures

  • Figure 1-1: Characteristics of an Ideal Drug Delivery System
  • Figure 2-1: Limitations of the Conventional Drug Delivery Systems
  • Figure 2-2: Diversification of the Novel Drug Delivery Platforms
  • Figure 3-1: History of Drug Delivery Technology from First Generation till Third Generation
  • Figure 3-2: Barriers to be Overcome by the Third Generation Drug Delivery System
  • Figure 4-1: Demonstration of the Targeted & Non-Targeted Drug Delivery
  • Figure 4-2: Controlled Drug Release is by Zero Order Mechanism
  • Figure 5-1: Differentiation of the Two Forms of the Diffusion Controlled Mechanisms
  • Figure 5-2: Mechanism of Encapsulation Dissolution Controlled System
  • Figure 5-3: Osmotic Release of the Drug Delivery with the Controlled Mechanism
  • Figure 5-4: Illustration of Erosion Mechanisms Found in Matrix Systems
  • Figure 6-1: Plasma Concentration v/s Time Profile in Conventional & Controlled Release
  • Figure 6-2: Comparison of Varied Modified Drug Release Systems
  • Figure 6-3: Illustration of Mechanism of Pulsatile Drug Release in Pulsincap
  • Figure 6-4: Classification Based Over the Technicality Erudition
  • Figure 6-5: Structural Differentiation among Varied Classified Drug Delivery Systems
  • Figure 6-6: Classification Based over the Route of Administration
  • Figure 7-1: Categorization of Polymeric Controlled Drug Delivery Devices
  • Figure 7-2: Varied Nanostructures Available for the Nanoparticulate Delivery System
  • Figure 8-1: Global - Controlled Release Drug Clinical Pipeline by Phase (%), 2018 till 2025
  • Figure 8-2: Global - Controlled Release Drug Clinical Pipeline by Phase (Number), 2018 till 2025
  • Figure 8-3: Global - Controlled Release Drug Clinical Pipeline by Phase (%),2018 till 2025
  • Figure 8-4: Global - Controlled Release Drug Clinical Pipeline by Phase (Number), 2018 till 2025
  • Figure 8-5: Global - Controlled Release Drug Clinical Pipeline by Country/Region (Number),2018 till 2025
  • Figure 8-6: Global - Controlled Release Clinical Drug Pipeline by Mode of Action (Number), 2018 till 2025
  • Figure 8-7: Global - Controlled Release Drug Clinical Pipeline by Drug Class (Number), 2018 till 2025
  • Figure 8-8: Global - Controlled Release Drug Clinical Pipeline by indication (Number), 2018 till 2025
  • Figure 9-1: Major Non-Invasive Administrative Routes of Insulin Delivery
  • Figure 9-2: Layout of the Controlled Drug Delivery Approaches in Cancer Therapeutics
  • Figure 9-3: Controlled Drug Delivery Approaches used to Deliver Drugs to CNS
  • Figure 10-1: Dosage Formulations for the Controlled Drug Delivery
  • Figure 10-2: Mechanism of the Controlled Drug Release of the Solid Dosage Forms
  • Figure 10-3: Representation of Categories of Liquid Dosage Form
  • Figure 10-4: Mechanism of Controlled Delivery of Parenteral Dosage Forms
  • Figure 10-5: General Forms of Oral Controlled Release System Mechanism
  • Figure 10-6: Schematic Diffusion Controlled Drug Release from Inert Matrices
  • Figure 10-7: Demonstration of the Osmotic Pump Drug Release Mechanism
  • Figure 11-1: Drug Delivery Share by Route of Administration, 2016
  • Figure 11-2: Global - Oral Drug Delivery Administration Market (US$ Billion), 2017 & 2025
  • Figure 11-3: Global - Injectable Drug Delivery Systems Market (US$ Billion), 2017 & 2025
  • Figure 11-4: Global - Implantable Device Market (US$ Billion), 2017 & 2025
  • Figure 11-5: Global - Topical Drug Delivery System Market (US$ Billions), 2017 & 2025
  • Figure 11-6: Global - Biodegradable Polymer Market (US$ Billions), 2017 & 2025
  • Figure 11-7: Global - Smart Polymers Market (US$ Billion), 2017 & 2025
  • Figure 11-8: Global - Nanomedicine Market (US$ Billion), 2017 - 2025
  • Figure 12-1: Accelerative Parameters of Controlled Drug Delivery Systems
  • Figure 12-2: Major Challenges Faced by Controlled Drug Delivery System
  • Figure 13-1: Illustration of Clinical Trials in Varied Segments for Controlled Drug Delivery
Back to Top
전화 문의
이용안내
 
BCC Research